Patient characteristics
| Characteristic . | Value (N = 141) . |
|---|---|
| Age, y | 58 [17-84] |
| WBC, ×109/L | 2.3 [0.3-207.0] |
| Hemoglobin, g/dL | 9.6 [3.8-14.3] |
| Platelets, ×109/L | 43 [3-464] |
| BM blasts, % | 32 [1-91] |
| Cytogenetics | |
| Diploid | 59 (42) |
| Poor risk | 38 (27) |
| Others | 42 (30) |
| Insufficient metaphases/not done | 2 (1) |
| CR1 response | |
| Refractory or CR1 duration <1 y | 88 (62) |
| CR1 duration ≥1 y | 38 (27) |
| Unknown | 15 (11) |
| Prior HSCT | 13 (9) |
| 2 cycles to best response | 19 (13) |
| Mutations* | |
| NPM1 | 22/57 (39) |
| NRAS/KRAS | 15/64 (23) |
| IDH2 | 16/79 (20) |
| IDH1 | 14/79 (18) |
| ASXL1 | 11/61 (18) |
| TET2 | 9/62 (15) |
| FLT3-ITD | 12/85 (14) |
| DNMT3A | 10/71 (14) |
| CEBPA | 9/69 (13) |
| RUNX1 | 8/62 (13) |
| WT1 | 6/61 (10) |
| PTPN11 | 6/68 (9) |
| FLT3-TKD | 7/85 (8) |
| EZH2 | 5/67 (7) |
| GATA2 | 4/62 (6) |
| Characteristic . | Value (N = 141) . |
|---|---|
| Age, y | 58 [17-84] |
| WBC, ×109/L | 2.3 [0.3-207.0] |
| Hemoglobin, g/dL | 9.6 [3.8-14.3] |
| Platelets, ×109/L | 43 [3-464] |
| BM blasts, % | 32 [1-91] |
| Cytogenetics | |
| Diploid | 59 (42) |
| Poor risk | 38 (27) |
| Others | 42 (30) |
| Insufficient metaphases/not done | 2 (1) |
| CR1 response | |
| Refractory or CR1 duration <1 y | 88 (62) |
| CR1 duration ≥1 y | 38 (27) |
| Unknown | 15 (11) |
| Prior HSCT | 13 (9) |
| 2 cycles to best response | 19 (13) |
| Mutations* | |
| NPM1 | 22/57 (39) |
| NRAS/KRAS | 15/64 (23) |
| IDH2 | 16/79 (20) |
| IDH1 | 14/79 (18) |
| ASXL1 | 11/61 (18) |
| TET2 | 9/62 (15) |
| FLT3-ITD | 12/85 (14) |
| DNMT3A | 10/71 (14) |
| CEBPA | 9/69 (13) |
| RUNX1 | 8/62 (13) |
| WT1 | 6/61 (10) |
| PTPN11 | 6/68 (9) |
| FLT3-TKD | 7/85 (8) |
| EZH2 | 5/67 (7) |
| GATA2 | 4/62 (6) |
Continuous variables are listed as median [range] and categorical variables as n (%) or n/N (%).
BM, bone marrow; CR1, first complete remission; WBC, white blood cell.
Mutations detected in ≥5% of tested patients are shown.